Table 1. Long-acting muscarinic antagonist/long-acting β2 agonist fixed-dose combinations.
| Variable | Glycopyrronium/indacaterol | Umeclidinium/vilanterol | Aclidinium/formoterol | Tiotropium/olodaterol | Glycopyrronium/formoterol | Tiotropium/formoterol |
|---|---|---|---|---|---|---|
| Abbreviation | GLY/IND | UMEC/VI | ACL/FF | TIO/OLO | GFF | TIO/FF |
| Delivered dose (μg) | 50/110 | 62.5/25 | 400/12 | 2.5/2.5 | 7.2/5 | 18/12 |
| Frequency | One inhalation once daily | One inhalation once daily | One inhalation twice daily | Two puffs once daily | Two inhalations twice daily | One puff once daily |
| Approved in China | √ | √ | – | √ | √ | – |
GLY/IND, glycopyrronium/indacaterol; UMEC/VI, umeclidinium/vilanterol; ACL/FF, aclidinium/formoterol; TIO/OLO, tiotropium/olodaterol; GFF, glycopyrrolate/formoterol fumarate; TIO/FF, tiotropium/formoterol.